Tofacitinib in Prevention of Photosensitivity in Lupus
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will determine whether the treatment intervention, tofacitinib:
- Impacts photosensitivity following ultraviolet light B (UVB) exposure in individuals
with systemic lupus and a history of cutaneous disease
- Is associated with changes in cutaneous disease activity in individuals with systemic
lupus and a history of cutaneous disease after a 25-day regimen of tofacitinib
- Is associated with changes in systemic lupus erythematosus (SLE) disease activity in
individuals with systemic lupus and a history of cutaneous disease after a 25-day
regimen of tofacitinib, and
- Is well tolerated in individuals with systemic lupus and a history of cutaneous disease.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Autoimmunity Centers of Excellence Rho Federal Systems Division, Inc.